E
E. Raymond
Researcher at Autonomous University of Barcelona
Publications - 2
Citations - 837
E. Raymond is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Tolerability & Tyrosine-kinase inhibitor. The author has an hindex of 1, co-authored 2 publications receiving 824 citations.
Papers
More filters
Journal ArticleDOI
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
José Baselga,D. Rischin,M. Ranson,H. Calvert,E. Raymond,D G Kieback,Stan B. Kaye,Luca Gianni,Adrian L. Harris,Thomas Björk,Steven D. Averbuch,A Feyereislova,H. Swaisland,Federico Rojo,Joan Albanell +14 more
TL;DR: ZD1839 treatment resulted in clinically meaningful disease stabilization across a range of tumor types and doses, and was generally well tolerated, with manageable and reversible AEs at doses up to 600mg/d and dose-limiting toxicity observed at 1,000 mg/d.
P h a s e I S a f ety, P harmacokinetic, a nd P harmacodynamic T rial of Z D1839, a S elective O ral E pidermal G rowth F actor R eceptor Tyrosine K inase I nhibitor, i n P atients W ith F ive S elected Solid T umor T ypes
J. Baselga,D. Rischin,M. Ranson,H. Calvert,E. Raymond,L. Gianni,Adrian L. Harris,Thomas Björk,A. Feyereislova,H. Swaisland,F. Rojo,J. Albanell +11 more
TL;DR: A phase I dose-escalating trial of oral ZD1839 150 mg/d to a maximum of 1,000mg/d given once daily for at least 28 days was conducted as discussed by the authors.